Societal CDMO Signs Project Expansion Agreements with Customers

Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, has signed work order extensions with multiple existing customers.

In a statement, Societal said that the expansion of the scope of work of existing customers continues to be a strategic area of growth for the company, complementing its parallel efforts dedicated to the securing of new customers.

The recently signed work expansions include: manufacturing of additional engineering batch of an antibiotic capsule formulation for the treatment of Staphylococcus aureus infections; analytical method transfer, evaluation, and validation for an investigational treatment for attention-deficit/hyperactivity disorder (ADHD); preparation and execution of a stability protocol, as well as a compatibility study, for an investigational cancer therapy; and clinical trial services focused on product encapsulation, packaging, and labeling for an investigational treatment for depression.

“We always feel gratified when an existing customer approaches us to expand their scope of work, as this offers the strongest indication that we are meeting their CDMO needs and delivering high quality results,” said Scott Rizzo, chief operating officer of Societal CDMO. “Additionally, these types of work extensions make important and meaningful contributions to Societal CDMO’s continued revenue growth. Our business development, project management and operations teams continue to deliver exceptional results in terms of growing our business and we look forward to supplementing these latest existing customer expansions with the announcement of additional new customer wins in the near future.”